Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors.